Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -66.12% is 61% above its 5-year average of -169.90%, near the high end of its 5-year range (-817.53%–-42.88%).
As of the fiscal period ended Tuesday, June 30, 2026. 38.88% above its 12-month average of -108.18%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -66.12%.
RETURN ON EQUITY (ROE)
-66.12%
RETURN ON EQUITY (ROE) AVG TTM
-108.18%
RETURN ON EQUITY (ROE) AVG 3Y
-175.06%
RETURN ON EQUITY (ROE) AVG 5Y
-169.90%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+38.88%
CURRENT VS 3Y AVG
+62.23%
CURRENT VS 5Y AVG
+61.08%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
-57.40%
vs the sector median at left
Unicycive Therapeutics, Inc.
Market Cap
$112.94M
Return on Equity (ROE)
-66.12%
TTM Avg
-108.18%
3Y Avg
-175.06%
5Y Avg
-169.90%
Market Cap
$112.57M
Return on Equity (ROE)
-105.40%
TTM Avg
-90.09%
3Y Avg
-60.23%
5Y Avg
-18.64%
Market Cap
$113.77M
Return on Equity (ROE)
-0.05%
TTM Avg
-43.47%
3Y Avg
9.13%
5Y Avg
-18.50%
Market Cap
$113.89M
Return on Equity (ROE)
-209.73%
TTM Avg
-196.07%
3Y Avg
-130.72%
5Y Avg
-67.26%
Market Cap
$114.46M
Return on Equity (ROE)
-478.26%
TTM Avg
-687.50%
3Y Avg
165.05%
5Y Avg
111.70%
Market Cap
$110.30M
Return on Equity (ROE)
-93.44%
TTM Avg
-8.16%
3Y Avg
13.24%
5Y Avg
13.24%
Market Cap
$115.67M
Return on Equity (ROE)
N/A
TTM Avg
129.36%
3Y Avg
-24207.46%
5Y Avg
-16163.58%
Market Cap
$109.14M
Return on Equity (ROE)
N/A
TTM Avg
326.93%
3Y Avg
83.50%
5Y Avg
24.39%
Market Cap
$116.76M
Return on Equity (ROE)
-22.45%
TTM Avg
-22.96%
3Y Avg
-17.88%
5Y Avg
-19.06%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | $112.94M | -66.12% | -108.18% | -175.06% | -169.90% |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | -105.40% | -90.09% | -60.23% | -18.64% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -0.05% | -43.47% | 9.13% | -18.50% |
| Genelux Corporation (GNLX)vs › | $113.89M | -209.73% | -196.07% | -130.72% | -67.26% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | -478.26% | -687.50% | 165.05% | 111.70% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | -93.44% | -8.16% | 13.24% | 13.24% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | N/A | 129.36% | -24207.46% | -16163.58% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $109.14M | N/A | 326.93% | 83.50% | 24.39% |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | -22.45% | -22.96% | -17.88% | -19.06% |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | -61.33% | -137.84% | -101.43% | -77.25% |
ROE
-66.1%
ROA
-48.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -66.12% |
| 2026-03-31 | -105.95% |
| 2025-12-31 | -87.94% |
| 2025-09-30 | -89.15% |
| 2025-06-30 | -191.72% |
| 2025-03-31 | -134.82% |
| 2024-12-31 | -494.27% |
| 2024-09-30 | -82.59% |
| 2024-06-30 | -74.15% |
| 2024-03-31 | -169.95% |
| 2023-09-30 | -817.53% |
| 2023-06-30 | -428.96% |
| 2023-03-31 | -276.66% |
| 2022-09-30 | -334.67% |
| 2022-06-30 | -152.63% |
| 2022-03-31 | -95.06% |
| 2021-12-31 | -60.77% |
| 2021-09-30 | -42.88% |
